Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx
Purpose: This phase II trial was designed to evaluate efficacy and safety of a highly intensified therapy in locally advanced squamous cell carcinoma of the oro-, hypopharynx and larynx. Methods: In this prospective, mono-centric, open-label, non-randomized phase II trial the single treatment arm co...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
November 2018
|
| In: |
Clinical and translational radiation oncology
Year: 2018, Jahrgang: 13, Pages: 64-73 |
| ISSN: | 2405-6308 |
| DOI: | 10.1016/j.ctro.2018.09.005 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1016/j.ctro.2018.09.005 Verlag, kostenfrei, Volltext: http://www.sciencedirect.com/science/article/pii/S240563081830065X 
|
| Verfasserangaben: | H. Hauswald, A. D. Jensen, J. Krauss, R. Haselmann, K. Lossner, S. Hartmann, C. Windemuth-Kieselbach, M. W. Münter, J. Debus |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1585802867 | ||
| 003 | DE-627 | ||
| 005 | 20220307102811.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181220s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ctro.2018.09.005 |2 doi | |
| 035 | |a (DE-627)1585802867 | ||
| 035 | |a (DE-576)515802867 | ||
| 035 | |a (DE-599)BSZ515802867 | ||
| 035 | |a (OCoLC)1264023089 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hauswald, Henrik |d 1977- |e VerfasserIn |0 (DE-588)131495739 |0 (DE-627)509817599 |0 (DE-576)298545810 |4 aut | |
| 245 | 1 | 0 | |a Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx |c H. Hauswald, A. D. Jensen, J. Krauss, R. Haselmann, K. Lossner, S. Hartmann, C. Windemuth-Kieselbach, M. W. Münter, J. Debus |
| 246 | 3 | 0 | |a phase two |
| 264 | 1 | |c November 2018 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 20.12.2018 | ||
| 520 | |a Purpose: This phase II trial was designed to evaluate efficacy and safety of a highly intensified therapy in locally advanced squamous cell carcinoma of the oro-, hypopharynx and larynx. Methods: In this prospective, mono-centric, open-label, non-randomized phase II trial the single treatment arm consisted of a combined induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil, followed by bioradiation with the monoclonal antibody cetuximab, carbon ion boost (24Gy(RBE) in 8 fractions) and IMRT (50Gy in 25 fractions). The trial was closed early due to slow accrual. Results: Eight patients (median age 52.5years) were enrolled into the trial. The median follow-up was 13months and the 12-months locoregional tumor control, progression-free survival and overall survival rates were 100.0% each. Complete remission was achieved in 7 patients. The most commonly late radiation adverse event was xerostomia (85.7% at 12months). Five serious adverse events with recovery were documented in 4 patients: mucositis grade 3 (n=2), decreased lymphocyte count grade 4, febrile neutropenia grade 4 and hypersensitivity grade 3 to cetuximab (n=1 each). Most symptom scales had their worst value at the last treatment day and recovered until the 4th follow-up visit. Conclusion: The study treatment was tolerable and promising. Reduced quality of life recovered for most aspects until the last follow-up visit. | ||
| 650 | 4 | |a Carbon ion therapy | |
| 650 | 4 | |a Cetuximab | |
| 650 | 4 | |a Head and neck cancer | |
| 650 | 4 | |a LAHNC | |
| 650 | 4 | |a Particle therapy | |
| 650 | 4 | |a SCCHN | |
| 700 | 1 | |a Jensen, Alexandra |d 1976- |e VerfasserIn |0 (DE-588)136129552 |0 (DE-627)577179020 |0 (DE-576)284704687 |4 aut | |
| 700 | 1 | |a Krauß, Jürgen |d 1960- |e VerfasserIn |0 (DE-588)120665301 |0 (DE-627)70490778X |0 (DE-576)292329083 |4 aut | |
| 700 | 1 | |a Haselmann, Renate |e VerfasserIn |0 (DE-588)1075341132 |0 (DE-627)833201700 |0 (DE-576)443408459 |4 aut | |
| 700 | 1 | |a Lossner, Karen |e VerfasserIn |0 (DE-588)1165154366 |0 (DE-627)1029319375 |0 (DE-576)510270581 |4 aut | |
| 700 | 1 | |a Münter, Marc |d 1972- |e VerfasserIn |0 (DE-588)121295591 |0 (DE-627)705363104 |0 (DE-576)292633645 |4 aut | |
| 700 | 1 | |a Debus, Jürgen |d 1964- |e VerfasserIn |0 (DE-588)1022671421 |0 (DE-627)717025780 |0 (DE-576)365774944 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and translational radiation oncology |d Amsterdam : Elsevier, 2016 |g 13(2018), Seite 64-73 |h Online-Ressource |w (DE-627)880788097 |w (DE-600)2885426-3 |w (DE-576)483742570 |x 2405-6308 |7 nnas |a Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx |
| 773 | 1 | 8 | |g volume:13 |g year:2018 |g pages:64-73 |g extent:10 |a Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ctro.2018.09.005 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S240563081830065X |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20181220 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 1022671421 |a Debus, Jürgen |m 1022671421:Debus, Jürgen |d 910000 |d 911400 |e 910000PD1022671421 |e 911400PD1022671421 |k 0/910000/ |k 1/910000/911400/ |p 9 |y j | ||
| 998 | |g 121295591 |a Münter, Marc |m 121295591:Münter, Marc |d 50000 |e 50000PM121295591 |k 0/50000/ |p 8 | ||
| 998 | |g 1165154366 |a Lossner, Karen |m 1165154366:Lossner, Karen |d 910000 |d 911400 |e 910000PL1165154366 |e 911400PL1165154366 |k 0/910000/ |k 1/910000/911400/ |p 5 | ||
| 998 | |g 1075341132 |a Haselmann, Renate |m 1075341132:Haselmann, Renate |d 910000 |d 911400 |e 910000PH1075341132 |e 911400PH1075341132 |k 0/910000/ |k 1/910000/911400/ |p 4 | ||
| 998 | |g 120665301 |a Krauß, Jürgen |m 120665301:Krauß, Jürgen |d 910000 |e 910000PK120665301 |k 0/910000/ |p 3 | ||
| 998 | |g 136129552 |a Jensen, Alexandra |m 136129552:Jensen, Alexandra |d 50000 |e 50000PJ136129552 |k 0/50000/ |p 2 | ||
| 998 | |g 131495739 |a Hauswald, Henrik |m 131495739:Hauswald, Henrik |d 910000 |d 911400 |e 910000PH131495739 |e 911400PH131495739 |k 0/910000/ |k 1/910000/911400/ |p 1 |x j | ||
| 999 | |a KXP-PPN1585802867 |e 3038862576 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"doi":["10.1016/j.ctro.2018.09.005"],"eki":["1585802867"]},"name":{"displayForm":["H. Hauswald, A. D. Jensen, J. Krauss, R. Haselmann, K. Lossner, S. Hartmann, C. Windemuth-Kieselbach, M. W. Münter, J. Debus"]},"recId":"1585802867","physDesc":[{"extent":"10 S."}],"title":[{"title":"Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx","title_sort":"Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx"}],"note":["Gesehen am 20.12.2018"],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"relHost":[{"id":{"zdb":["2885426-3"],"eki":["880788097"],"issn":["2405-6308"]},"title":[{"title_sort":"Clinical and translational radiation oncology","title":"Clinical and translational radiation oncology"}],"part":{"year":"2018","pages":"64-73","extent":"10","text":"13(2018), Seite 64-73","volume":"13"},"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"note":["Gesehen am 26.05.2020"],"origin":[{"publisherPlace":"Amsterdam","dateIssuedDisp":"[2016]-","publisher":"Elsevier"}],"pubHistory":["Volume 1 (December 2016)-"],"disp":"Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynxClinical and translational radiation oncology","recId":"880788097","physDesc":[{"extent":"Online-Ressource"}]}],"person":[{"display":"Hauswald, Henrik","given":"Henrik","role":"aut","family":"Hauswald"},{"role":"aut","given":"Alexandra","family":"Jensen","display":"Jensen, Alexandra"},{"display":"Krauß, Jürgen","role":"aut","given":"Jürgen","family":"Krauß"},{"display":"Haselmann, Renate","role":"aut","given":"Renate","family":"Haselmann"},{"family":"Lossner","given":"Karen","role":"aut","display":"Lossner, Karen"},{"family":"Münter","role":"aut","given":"Marc","display":"Münter, Marc"},{"display":"Debus, Jürgen","role":"aut","given":"Jürgen","family":"Debus"}],"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"November 2018"}]} | ||
| SRT | |a HAUSWALDHEPHASEIISTU2018 | ||